Selective reduction by some vasodilators and the prostaglandin antagonist SC-19220 of a response to the algesic effect of bradykinin.
D000109:Acetylcholine / Q000494:pharmacology; D000628:Aminophylline / Q000494:pharmacology; D000818:Animals; D001920:Bradykinin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D003864:Depression, Chemical; D012531:Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide / Q000494:pharmacology*; D003989:Dibenzoxazepines / Q000494:pharmacology*; D005260:Female; D008297:Male; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology*; D010208:Papaverine / Q000494:pharmacology; D011817:Rabbits; D014665:Vasodilator Agents / Q000494:pharmacology*; D014700:Verapamil / Q000494:pharmacology
D003989:Dibenzoxazepines; D014665:Vasodilator Agents; D012531:Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide; D000628:Aminophylline; D014700:Verapamil; D010208:Papaverine; D000109:Acetylcholine; D001920:Bradykinin